Table 5 Role of CRISPR/Cas9 in cancer modeling
From: CRISPR/Cas9: the Jedi against the dark empire of diseases
Type of cancer | Method of CRISPR/Cas9Â delivery | Conclusion | Reference |
|---|---|---|---|
Pancreatic cancer | Transfection based multiplexed delivery into mice | Editing of multiple gene sets in pancreatic cells of mice | [54] |
Acute myeloid cancer (AML) | Lentiviral based delivery into Hematopoirtic stem cells | Loss of function in nine targeted genes analogous to AML | [56] |
Liver cancer | Hydrodynamic injection into wild type mice | Mutation in the Pten and p53 genes leading to liver cancer in mice | [59] |
Breast cancer | Plasmid transfection into JygMC (mouse cell line) | The stem cell marker Cripto-1 was shown to be as a breast target | [60] |
Pancreatic cancer | Lentivirus/Adenovirus based delivery intosomatic pancreatic cells of mice | Knockout of gene Lkb1 | [61] |
Lung cancer | Plasmid transfection into human cell line (HEK 293) | Chromosomal rearrangement among EML4 and ALK genes | [62] |
Lung cancer | Lentivirus/Adenovirus mediated | Gain of function of KRS and loss of function of p53 and Lkb1 | [63] |
Colon cancer | Plasmid transfection into DLD1 and HCT116Â cell lines (human) | Loss of function in protein kinase c subgroups | [64] |
Colorectal cancer | Electropolation into organoids intestinal epithelium (human) | Loss of function and directed mutation in APC, SMAD4, TP 53 and KRAS genes | [65] |
Gliobastoma Medulloblastoma | Postnatal PEI-mediated transfection and in utero electroporation into mice | Deletion of TSGs (Ptch1, Trp 53, Pten and Nf1) | [66] |
Renal cancer | Renca (mouse cell line) | Knockout of TSG VHL to induce cancer | [67] |